Anixa Biosciences Inc Asset Resilience Ratio
Anixa Biosciences Inc asset resilience ratio. Anixa Biosciences Inc (ANIX) has an Asset Resilience Ratio of 82.70% as of July 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Anixa Biosciences Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Anixa Biosciences Inc (1999–2025)
Asset resilience ratio of Anixa Biosciences Inc from 1999 to 2025. This chart shows how Anixa Biosciences Inc's Asset Resilience Ratio has changed over time. Read Anixa Biosciences Inc debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Anixa Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Anixa Biosciences Inc asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $12.47 Million | 82.7% |
| Total Liquid Assets | $12.47 Million | 82.70% |
Asset Resilience Insights
- Very High Liquidity: Anixa Biosciences Inc maintains exceptional liquid asset reserves at 82.70% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Anixa Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Anixa Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Anixa Biosciences Inc Asset Resilience Ratio by Year (1999–2025)
Anixa Biosciences Inc asset resilience ratio by year from 1999 to 2025. The table below shows the annual Asset Resilience Ratio data for Anixa Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-10-31 | 86.63% | $13.93 Million | $16.08 Million | +0.24pp |
| 2024-10-31 | 86.39% | $18.65 Million | $21.59 Million | -3.45pp |
| 2023-10-31 | 89.84% | $22.93 Million | $25.52 Million | +32.87pp |
| 2022-10-31 | 56.97% | $17.33 Million | $30.41 Million | +38.77pp |
| 2021-10-31 | 18.20% | $6.60 Million | $36.26 Million | -9.73pp |
| 2020-10-31 | 27.93% | $2.64 Million | $9.45 Million | -9.41pp |
| 2019-10-31 | 37.34% | $2.35 Million | $6.29 Million | +6.32pp |
| 2018-10-31 | 31.01% | $2.00 Million | $6.45 Million | -8.70pp |
| 2017-10-31 | 39.72% | $3.50 Million | $8.81 Million | +26.39pp |
| 2016-10-31 | 13.33% | $750.00K | $5.63 Million | -12.38pp |
| 2015-10-31 | 25.71% | $2.40 Million | $9.34 Million | -1.90pp |
| 2014-10-31 | 27.61% | $2.50 Million | $9.06 Million | +18.78pp |
| 2012-10-31 | 8.83% | $500.00K | $5.66 Million | -17.18pp |
| 2011-10-31 | 26.01% | $2.25 Million | $8.65 Million | +18.40pp |
| 2009-10-31 | 7.61% | $749.94K | $9.85 Million | -11.62pp |
| 2008-10-31 | 19.24% | $1.44 Million | $7.50 Million | -2.15pp |
| 2007-10-31 | 21.39% | $400.00K | $1.87 Million | +19.35pp |
| 2006-10-31 | 2.04% | $38.00K | $1.86 Million | -25.31pp |
| 2005-10-31 | 27.35% | $401.00K | $1.47 Million | +25.94pp |
| 2000-10-31 | 1.41% | $96.87K | $6.89 Million | -4.77pp |
| 1999-10-31 | 6.17% | $500.00K | $8.10 Million | -- |
About Anixa Biosciences Inc
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged … Read more